

RECEIVED  
CENTRAL FAX CENTER

MAY 26 2005

**Facsimile**

1613 Prospect Parkway  
Fort Collins, CO 80525  
970-493-7272 (l)  
970-491-9976 (f)

Date: May 26, 2005

**PLEASE DELIVER THE FOLLOWING PAGE(S) TO:**

Name: Examiner Patrick J. Nolan, Ph.D., Group Art Unit 1644  
Facsimile Number: 703-872-9306  
Telephone Number: 571-272-0847  
Pages: 3 (including this page)  
Subject: Attorney File No. AL-2-C4  
U.S. Patent Application Serial No: 09/662,293  
From: Richard J. Stern, Ph.D. (970-493-7272 - Ext 4174)

---

Interview Summary is attached.

---

**CONFIDENTIALITY NOTICE**

The documents accompanying this FACSIMILE transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in this transmission is strictly prohibited. If you have received this transmission in error, please immediately notify us by telephone and mail the original transmission to us. Thank you.

ATTN: MAIL STOP AMENDMENT  
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**  
**CENTRAL FAX CENTER**

In Re the Application of:

Group Art Unit: 1644

**MAY 26 2005**McCall, Catherine A.  
Hunter, Shirley Wu  
Weber, Eric R.

Examiner: Nolan, Patrick J.

Serial No.: 09/662,293

INTERVIEW SUMMARY

Filed: September 14, 2000

Atty. File No.: AL-2-C4

For: "NOVEL DERMATOPHAGOIDES  
NUCLEIC ACID MOLECULES,  
PROTEINS AND USES THEREOF"

## CERTIFICATE OF FACSIMILE TRANSMISSION

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING FACSIMILE TRANSMITTED TO EXAMINER  
PATRICK J. NOLAN, 1644, FAX NO. 703-872-9306,  
ADDRESSED TO MAIL STOP AMENDMENT,  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VA 22313-1450, ON THIS 26TH DAY OF MAY  
2005.HESKA CORPORATION  
By: *Susan Gordon*  
Susan GordonMail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

On May 23, 2005, Applicants' representatives, Richard Stern and Theresa Brown, conducted a telephonic interview with Examiner Patrick Nolan to discuss the rejection of Claims 52-57 and 60-65 under 35 U.S.C. §112, first paragraph, for lack of enablement. The Examiner suggested Applicants amend the language of Claims 52, 56 and 60 to state the claimed protein must bind IgE from a patient allergic to *Dermatophagoides farinae*. Applicants agreed to make this amendment. In addition, Applicants will be canceling Claim 65 drawn to a therapeutic composition for treating an allergic response, and submitting new Claim 66, which will substantially track Claim 65 but will be drawn to a composition for treating an allergic response.

Finally, Applicants noted the claim is limited to mapB proteins which are defined in the specification. Applicants will submit an amended claim set to the Examiner in a Response After Final.

Respectfully submitted,

Dated: May 26, 2005

By:   
Richard J. Stern, Ph.D.  
Registration No. 50,668  
Heska Corporation  
3760 Rocky Mountain Avenue  
Loveland, Colorado 80538  
Telephone: (970) 493-7272  
Facsimile: (970) 491-9976